EUDA Health Inks Tri-Party MOU to Develop Next-Gen iPSC and NK-TCR Cell Therapies
EUDA has more than doubled off its 52-week low of $5.26 on light trading volume (0.1× avg).
Summary
EUDA Health signed a non-binding MOU with GO POSB Organoids and Shenzhen Inno to co-develop, manufacture, and commercialize off-the-shelf oncology cell therapies derived from iPSCs. The collaboration targets cancer treatment and wellness applications, marking a strategic push into next-generation cell therapies. This follows EUDA's recent Nasdaq compliance regain and product launches, signaling an aggressive pivot toward high-value biotech assets. The MOU is early-stage and non-binding, but it opens a new therapeutic vertical for a company with a $47M market cap. Execution risk is high given EUDA's limited in-house R&D and recent dilutive financing history, but the announcement could attract speculative interest in the stock.
At the time of this announcement, EUDA was trading at $19.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.4M. The 52-week trading range was $5.26 to $86.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.